Novartis: will not move forward with UK anti-cholesterol drug trial
BERLIN (Reuters) – Novartis said on Wednesday that it had decided not to move forward with ORION-17, the UK-based primary prevention trial originally planned as part of its partnership with NHS England to investigate the potential of the anti-cholesterol drug Leqvio. “After careful evaluation, we have decided not to move forward with ORION-17,” a spokesperson said in an emailed statement. “We continue to have very high ambitions for Leqvio and […]